Drug intelligence / Profile preview

MINT91

Development stage: Preclinical
Lead developer: Chugai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

MINT91 is an investigational small molecule being developed by Chugai Pharmaceutical for the treatment of solid tumors. As of early 2026, the drug is part of Chugai's internal pipeline, though its specific biological target and mechanism of action have not been publicly disclosed. It is currently being evaluated for its potential in treating various types of solid malignancies.

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)

Beyond the preview

Go deeper on MINT91.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MINT91.

Explore the full profile